Antiarrhythmics or Ablation for Ventricular Tachycardia 2

Summary

A multicenter, randomized clinical trial to assess whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia (VT).

Conditions

• Ventricular Tachycardia (VT)

Interventions

DRUG

Antiarrythmic Drug Therapy

Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)

PROCEDURE

Catheter ablation

Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.

Sponsors & Collaborators

• Heart and Stroke Foundation of Canada

  collaborator OTHER

• Abbott Medical Devices

  collaborator INDUSTRY

• Biosense Webster, Inc.

  collaborator INDUSTRY

• Ottawa Heart Institute Research Corporation

  collaborator OTHER

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Cardiac Arrhythmia Network of Canada

  collaborator OTHER

• Abbott

  collaborator INDUSTRY

• Nova Scotia Health Authority

  collaborator OTHER

• John Sapp

  lead OTHER

Principal Investigators

• John L Sapp, MD FRCPC · Nova Scotia Health Authority

• Ratika Parkash, MD MSc FRCPC · Nova Scotia Health Authoriry

• Anthony L Tang, MD FRCPC · London Health Sciences Centre

• George A Wells, BSc MSc PhD · Ottawa Heart Institute Research Corporation

• William G Stevenson, MD · Brigham and Women's Hospital

• Jeff Healey, MD FRCPC · Population Health Research Institute, McMaster University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-10-31

Primary Completion

2024-06-06

Completion

2024-06-30

Countries

• United States
• Canada
• France

Study Locations